Prosecution Insights
Last updated: November 04, 2026
Application No. 18/708,861

ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS

Non-Final OA §103§112§DOUBLEPATENT
Filed
May 09, 2024
Priority
Nov 10, 2021 — EU 21207536.0 +1 more
Examiner
STONEBRAKER, ALYSSA RAE
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nerviano Medical Sciences S.r.l.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
69 granted / 116 resolved
-0.5% vs TC avg
Strong +50% interview lift
Without
With
+49.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
46 currently pending
Career history
184
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
34.2%
-5.8% vs TC avg
§102
10.4%
-29.6% vs TC avg
§112
28.5%
-11.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 116 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 12-16 and 19-20 have been cancelled; and claims 2, 6-7, and 21 have been amended, as requested in the preliminary amendment filed on 11/26/2024. Following the amendment, claims 1-11, 17-18, and 21-24 are pending in the instant application. Claims 1-11, 17-18, and 21-24 are under examination in the instant office action. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Furthermore, it is noted that the certified copy of the foreign priority document is in English, and as such the claim to foreign priority has been perfected. Claims 1-11, 17-18, and 21-24 have an effective filing date of November 10, 2021 corresponding to EP21207536.0. Information Disclosure Statement The information disclosure statement filed 05/09/2024 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein struckthrough has not been considered. Claim Objections Claims 1-3 are objected to because of the following informalities: the claims recite “aminoacids”, but should read “amino acids”. Appropriate correction is required. Claims 6 and 21 are objected to because of the following informalities: the claims recite “that binds or reactively associates or make a complex with a receptor”, but should read “that binds or reactively associates or makes a complex with a receptor”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-3, 6, 8, 10-11, 17-18, 21, and 24 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a WRITTEN DESCRIPTION rejection. PNG media_image1.png 286 262 media_image1.png Greyscale The claims are generally drawn to genera of anthracycline derivatives, anthracycline-linker reagents, and ADCs thereof, generally useful in the treatment of cancer, wherein generally, the anthracycline of the invention Ant corresponds to formula (II): PNG media_image2.png 240 520 media_image2.png Greyscale wherein X is O or NH and A is a heterocycle (Het) or carbocycle (Cb) selected from the group consisting of (IIIa)-(IIIe): wherein R is independently H or a straight or branched C1-C6 alkyl and wherein n is an integer from 0 to 6. It is further noted that L is a linker of formula (VI), corresponding to W-PE-RM, wherein W is independently null or a self-immolative system selected from (Va)-(Vc): PNG media_image3.png 154 708 media_image3.png Greyscale PNG media_image4.png 150 700 media_image4.png Greyscale wherein R1 and R2 are each independently H, a halogen, methyl, ethyl, or straight or branched C1-C4 hydroxyalkyl; PE is independently null or a dipeptidic or tripeptidic moiety consisting of any combination of natural L-amino acids and unnatural D-amino acids; and RM is a reactive moiety selected from the group consisting of (VIa)-(VIc): wherein R3 and R4 are each independently H, a halogen, methyl, ethyl, straight or branched C1-C4 hydroxyalkyl, straight or branched C1-C4 haloalkyl, or R3 and R4 taken together form a 3- to 6-membered carbocycle; R5 is H, C1-C3 alkyl, or an electron-withdrawing group comprising NO2 or a CN group; and wherein r is an integer from 0 to 7. Thus, the claims identify the products of the invention (i.e., anthracycline derivatives, anthracycline-linker reagents, and ADCs thereof) by the generic structures, and their subsequent combinations, as provided above. Thus, the claims encompass a vast genus of anthracycline derivatives, anthracycline-linker reagents, and ADCs thereof comprising variable structural groups/elements. The instant specification discloses the full structures of 16 anthracycline-linker reagents, and subsequently 16 ADCs thereof, wherein said anthracycline-linker reagents/ADCs comprise 8 anthracycline derivatives (see Pages 14-20). Thus, the instant specification discloses making 16 anthracycline-linker reagents, and subsequently 16 ADCs thereof, wherein said anthracycline-linker reagents/ADCs comprise 8 anthracycline derivatives and describes the complete structures of said anthracycline-linker reagents/ADCs and anthracycline derivatives. Notably, all of the disclosed structures comprise: A that is a heterocyclic or carbocyclic group selected from (IIIa)-(IIIc); L that (i) comprises W, wherein W is of (Va), (ii) comprises PE, wherein PE is a dipeptide and wherein the dipeptides are Valine-Citrulline or Valine-Alanine, and (iii) comprises RM, wherein RM is of (VIa). The specification fails to disclose any other structures comprising: A that is (IIId) or (IIIe), L wherein W and/or PE are null, L wherein W is (Vb) or (Vc), L wherein PE is a tripeptide, nor L wherein RM is (VIb) or (VIc). To provide adequate written description and evidence of possession of the claimed anthracycline derivative, anthracycline-linker reagent, and ADC genera, the instant specification can structurally describe representative structural variants that still function to, for example, treat cancer, or describe structural features common to the members of the genus, which features constitute a substantial portion of the genus. Alternatively, the specification can show that the claimed invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics (see University of California v. Eli Lilly and Co., 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997) and Enzo Biochem, Inc. V. Gen-Probe Inc.). In this case, the only factor present in the claims is a recitation of the partial structure(s) as provided above. The instant specification fails to describe structural features common to the members of the genera, which features constitute a substantial portion of the genus because the instant specification fails to disclose representative structural variants comprising certain claimed structural elements that still retain their function. Other than for the structures provided at Pages 14-23 of the instant specification, the specification fails to provide the exemplary species comprising: A that is (IIId) or (IIIe), L wherein W and/or PE are null, L wherein W is (Vb) or (Vc), L wherein PE is a tripeptide, nor L wherein RM is (VIb) or (VIc) that still retain their function. The instant specification fails to describe a representative number of structural variants for the anthracycline derivative, anthracycline-linker reagent, and ADC genera that retain their function. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed structural elements, and their subsequent combinations, required to make the claimed anthracycline derivatives, anthracycline-linker reagents, and ADCs. Although Applicants may argue that it is possible to screen for anthracycline derivatives, anthracycline-linker reagents, and ADCs that retain their function, for example in treating cancer, the court found in (Rochester v. Searle, 358 F.3d 916, Fed Cir., 2004) that screening assays are not sufficient to provide adequate written description for an invention because they are merely a wish or plan for obtaining the claimed chemical invention. “As we held in Lilly, “[a]n adequate written description of a DNA … ‘requires a precise definition, such as by structure, formula, chemical name, or physical properties,’ not a mere wish or plan for obtaining the claimed chemical invention.” 119 F.3d at 1566 (quoting Fiers, 984 F.2d at 1171). For reasons stated above, that requirement applies just as well to non-DNA (or RNA) chemical inventions.” Knowledge of screening methods provides no information about the structure of any future anthracycline derivatives, anthracycline-linker reagents, and ADCs yet to be discovered that may function as claimed. Given the lack of representative examples to support the full scope of the anthracycline derivative, anthracycline-linker reagent, and ADC genera, the present claims lack adequate written description. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 6, 8, 10-11, 17-18, and 21-24 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the claim recites “A is a heterocycle (Het) or carbocycle (Cb) selected from the group consisting of (IIIa)-(IIIe)…”. It is specifically noted that at Page 5 of the instant specification, the term “heterocyclyl” is defined as referring “to a saturated or unsaturated non-aromatic 5- to 7- membered carbocyclic ring, wherein 1 to 3 carbon atoms are replaced by heteroatoms selected from nitrogen, oxygen and sulfur, wherein said heteroatoms may be directly connected to each other, nitrogen and sulfur may optionally be oxidized, nitrogen may optionally be quaternized or bring a substituent” (emphasis added). As such, the general definition of a heterocyclic group renders claim 1 indefinite because it becomes unclear as to how many additional heteroatoms are/can be included, what those heteroatoms may be, and what heteroatoms may or may not be oxidized, quaternized, or comprise a substituent; the definition provides additional compounding limitations that render the metes and bounds of the claim ambiguous. Claims 1, 6, 8, 10-11, 17-18, 21, and 24 are included in this rejection as they all depend from and/or incorporate claim 1. Further regarding claim 2, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. It is unclear if the limitation following the recitation of “preferably” is intended as merely being exemplary, or if the limitation following the recitation of “preferably” is a required feature of the claim. See MPEP § 2173.05(d). Regarding claim 21, the claim recites the product of claim 1 (i.e., anthracycline -linker reagent), wherein said product is used as an intermediate for the preparation of antibody-drug conjugate compounds of Formula (Ia). Thus, claim 21 is a product claim further reciting a use of said product; as such, it is unclear if the claim is intended to claim a product or a method, and therefore the scope of the claimed invention is unclear. For the purposes of examination, claim 21 is being interpreted as a product claim. Regarding claims 22 and 23, it is noted that: (i) claim 22 recites “[a]n anthracycline derivative of formula (II)…”, however claim 22 does not recite a structure corresponding to formula (II), nor does the claim reference a previous claim wherein the structure of formula (II) is defined; and (ii) claim 23 depends from claim 22, and further recites “the preparation of anthracycline-linker reagent compounds of formula (I)”, however claim 23 does not recite a structure corresponding to formula (I), nor does the claim reference a previous claim wherein the structure of formula (I) is defined As such, the claims make reference to structure(s) that are undefined, rendering the claims indefinite. Further regarding claim 23, the claim recites the product of claim 22 (i.e., anthracycline derivative), wherein said product is used for preparing anthracycline-linker reagent compounds. Thus, claim 23 is a product claim further reciting a use of said product; as such, it is unclear if the claim is intended to claim a product or a method, and therefore the scope of the claimed invention is unclear. For the purposes of examination, claim 23 is being interpreted as a product claim. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-11, 17-18, and 51-24 are rejected under 35 U.S.C. 103 as being unpatentable over each of: US 8,900,589; US 8,389,697; and US 9,695,240. It is specifically noted that US 8,389,697 and US 9,695,240 are a continuation and a divisional, respectively, of US 8,900,589. As such, all three of the above-listed patents have the same disclosure. For the rejection below, US 8,900,589 (herein after referred to as “Beria”) is being used. Beria teaches conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors (Abstract). A first aspect of the invention relates to conjugates of an anthracycline derivative of the formula (I): [Ant-L-Z]m-T wherein Ant is an anthracycline derivative residue, L is a linker, Z is a spacer, m is an integer from 1 to 30, and T is a carrier such as a protein, peptide, monoclonal or polyclonal antibody or a chemically modified derivative thereof suitable to be attached to the [Ant-L-Z-] moiety or moieties, or a polymeric carrier (Column 22, Lines 57-64; see Column 4, Lines 55-64 for component definitions). Preferably, the anthracycline derivative residue that Ant represents can be released to give an anthracycline derivative of formula (IIA), as reproduced below (Columns 22-23): PNG media_image5.png 316 304 media_image5.png Greyscale It is specifically noted that the above anthracycline derivative corresponds to Ant of the instant claims, absent A of the instantly claimed Ant structure, wherein X is O. In an exemplary embodiment, Beria provides an anthracycline derivative conjugate or a pharmaceutically PNG media_image6.png 318 386 media_image6.png Greyscale salt thereof of the formula (Ia), as reproduced below: PNG media_image7.png 192 361 media_image7.png Greyscale wherein R1 is H, a hydroxy, or a methoxy group; R2 is a C1-C5 alkoxy group , m is an integer from 1 to 30, T is a carrier such as a protein, peptide, monoclonal or polyclonal antibody or a chemically modified derivative thereof suitable to be attached to the [Ant-L-Z-] moiety or moieties, or a polymeric carrier, and L1 is a linker of formula (III) or (IV): wherein B is a C1-C6 alkylene moiety optionally interrupted, and v, j, k, and y are independently 0 or 1 (Column 23, Lines 21-67; see Columns 4-5 for component definitions except L1). It is specifically noted that, in the instance provided above, the anthracycline derivative residue which Ant represents is tether to the linker L1 through an acetalic bond that involves the primary alcohol at the C-14 of the anthracycline skeleton (Column 24, Lines 1-4). The invention further provides drug-linker intermediates, including anthracycline derivatives of formula (IIc): Ant-L-(Z)m-X wherein Ant is selected from the following: PNG media_image8.png 388 716 media_image8.png Greyscale wherein the wavy line indicates the attachment of L; L is a linker selected from -N(R)-, -N(R)m(C1-C12 alkylene)-, -N(R)m(C2-C8 alkenylene)-, -N(R)m(C2-C8 alkynylene)-, PNG media_image9.png 270 368 media_image9.png Greyscale -N(R)m(CH2CH2O)n-, and the below listed structures: wherein the wavy lines indicate the attachments to Ant and Z; and further wherein Z is an optional spacer selected from -CH2C(O)-, -CH2C(O)NR(C1-C12 alkylene)-, and the below listed structures: PNG media_image10.png 300 644 media_image10.png Greyscale wherein X is a reactive functional group selected from maleimide, thiol, amino, bromide, p-toluenesulfonate, iodide, hydroxyl, carboxyl, pyridyl disulfide, and N-hydroxysuccinimide; PNG media_image11.png 446 742 media_image11.png Greyscale R is H, C1-C12 alkyl, or C6-C20 aryl; R1 and R2 are independently selected from an amino acid side chain; Z1 is selected from -(C1-C12 alkylene)-, -(C2-C8 alkenylene)-, -(C2-C8 alkynylene)-, and -(CH2CH2O)n-, m is 0 or 1; and n is 1 to 6 (Columns 31-33). An exemplary drug-linker intermediate embodiment of formula (IIc) comprising an anthracycline drug moiety and a linker-spacer unit includes compound 55, as reproduced below (Column 38): It is specifically noted that the anthracycline-linker intermediate above comprises groups corresponding to the instantly claimed A group and L, wherein A is a heterocycle group of instant formula (IIIa) and L is a linker of instant formula (VI) wherein W is that of instant formula (Va) wherein R1 and R2 are each H, PE is a dipeptide of citrulline and valine, and RM is of instant formula (VIa) wherein r is an integer of 5. An exemplary synthetic route from PNU- PNG media_image12.png 708 1038 media_image12.png Greyscale 159682 C-14 carboxyl derivative 56 and linker-spacer intermediate 60 is provided in Figure 7d, as reproduced below: PNG media_image13.png 300 626 media_image13.png Greyscale An exemplary antibody-drug conjugate (ADC) provided by the invention includes that reproduced below: PNG media_image14.png 318 338 media_image14.png Greyscale wherein D is a drug unit (i.e., anthracycline drug unit) and p is an integer from 1 to 8 (Columns 80-81). It is further noted that Beria teaches an anthracycline derivative intermediate corresponding to compound 57, as reproduced below, in Example 3c (Columns 121-122): Beria teaches that in one embodiment, the ADCs of the invention specifically bind to a receptor encoded by an ErbB gene (e.g., EGFR, HER2, HER3 and HER4) and in some embodiments the ADC may specifically bind to the extracellular domain of the HER2 receptor and the antibody (Ab) of formula (IIc) is a humanized antibody such as huMAb4D5-8 (i.e., trastuzumab) (Columns 43-44). Additionally, Beria teaches that drug loading of ADCs may range from 1 to 8 drugs (D) per antibody (Ab); the average number of drugs per antibody in preparations of ADC from conjugation reactions may be characterized by conventional means such as mass spectroscopy, ELISA assay, electrophoresis, and HPLC and wherein the quantitative distribution of ADC in terms of p may also be determined (Column 84, Lines 1-9). It is specifically noted that Table 2 at Columns 86-87 provides exemplary ADCs comprising anthracycline derivates as the drug, wherein the average drug/antibody ratio (DAR) is further provided; the average DARs of anthracycline derivative-containing ADCs, including ADCs comprising trastuzumab (i.e., “Tr”), are 2.18, 2.4, 1.25, 1.6, 2.57, 2.43, 1.43, 2.13 and 1.65. Beria further teaches that ADCs of the invention are useful as antitumor agents; a mammal (e.g., a human or animal) may therefore be treated by a method comprising administering thereto a pharmaceutically effective amount of a conjugate of the invention (Column 105, Lines 28-32). The ADCs may be used to treat various diseases or disorders in a patient, such as cancer and autoimmune conditions including those characterized by the overexpression of a tumor-associated antigen (Column 105, Lines 34-37). Exemplary cancers to be treated include those listed at Column 106, Lines 7-23; for example, some cancers to be treated include carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies, wherein some particular examples include endometrial or uterine carcinoma, hepatic carcinoma, anal carcinoma, penile carcinoma, adenocarcinoma of the lung and squamous carcinoma of the lung, and thyroid cancer. Beria further teaches that ADCs may be formulated as pharmaceutical compositions with a pharmaceutically acceptable carrier or diluent, wherein any appropriate carrier or diluent may be used (Column 102, Lines 51-53). ADCs may be combined in a pharmaceutical combination formulation, or dosing regimen as combination therapy, with a second compound having anti-cancer properties; the second compound may be a chemotherapeutic agent, cytotoxic agent, cytokine, growth inhibitory agent, anti-hormonal agent, aromatase inhibitor, protein kinase inhibitor, lipid kinase inhibitor, anti-androgen, antisense oligonucleotide, ribozyme, gene therapy vaccine, anti-angiogenic agent and/or cardioprotectant (Column 106, Lines 48-60). PNG media_image5.png 316 304 media_image5.png Greyscale However, it is noted that the exemplary structural embodiments above utilize PNU-159682 C-14 carboxyl derivative compound 56, wherein the -OH used for conjugation to a linker is attached to the carbonyl carbon. It is specifically noted that Beria also teaches that PNU-159682 has been shown to be remarkably more cytotoxic than nemorubicin and doxorubicin in vitro, and was effective in vivo tumor models, wherein PNU-159682 is named as 3'-deamino-3",4'-anhydro-[2"(S)-methoxy-3"(R)-oxy-4"-morpholinyl]doxorubicin, and has the structure reproduced below (Column 4, Lines 1-32): It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to substitute exemplary starting compound 56 of Beria with PNU-159682, wherein such a substitution would yield the below listed structures: PNG media_image15.png 836 780 media_image15.png Greyscale One would have been motivated to make such a substitution to arrive at the above-listed structures because Beria teaches that PNU-159682 has been shown to be remarkably more cytotoxic than nemorubicin and doxorubicin in vitro, and was effective in vivo tumor models; thus one of ordinary skill in the art would have been motivated to substitute compound 56 of Beria with PNU-159682 (i.e., substitute one anthracycline for another) because such a substitution would have reasonably been expected to yield compounds useful in making ADCs wherein said compounds and ADCs thereof would reasonably be expected to be useful in the treatment of, for example, cancer wherein the efficacy of anthracyclines, including those with structures of Beria compound 56 and PNU-159682, are established as well as their use in ADCs and synthetic approaches associated therewith. Additionally, specifically with regard to instant claims 21 and 23, it is noted that the recited uses of the claimed products do not result in a structural difference between the instantly claimed products and the products rendered obvious by Beria, and as such claims 21 and 23 are also rendered obvious by Beria. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-11, 17-18, and 51-24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 7-12, 15, and 18 of U.S. Patent No. 8,900,589 (herein after referred to as “first reference patent”) in view of each of: US 8,900,589; US 8,389,697; and US 9,695,240. It is specifically noted that US 8,389,697 and US 9,695,240 are a continuation and a divisional, respectively, of US 8,900,589. As such, all three of the above-listed patents have the same disclosure. The teachings of the disclosure of US 8,900,589 (herein after referred to as “Beria”) are provided in the 103 section above. First reference patent claim 1 is drawn to an antibody-drug conjugate (ADC) compound comprising an antibody covalently attached by a linker L and an optional spacer Z to one or more anthracycline derivative drug moieties D, the compound having the formula PNG media_image16.png 867 350 media_image16.png Greyscale (D-L-(Z)m)p-Ab or a pharmaceutically acceptable salt thereof, wherein: PNG media_image17.png 1047 360 media_image17.png Greyscale n is 1 to 6; p is an integer from 1 to 8; and wherein Ab is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(36), wherein it is specifically noted that (17) is HER2 (ErbB2). First reference patent claim 2 further limits the ADC of claim 1, wherein R1 and R2 are each independently selected from a list of structures, wherein it is specifically noted that said list of structures include isopropyl (side chain of amino acid valine) and -(CH2)3NHCONH2 (side chain of amino acid citrulline). First reference patent claims 3-4 further limit the ADC of claim 1 wherein, respectively: (i) spacer Z comprising a para-aminobencyloxycarbonyl (PAB) group; and (ii) the linker-spacer unit L-Z comprises a meleimidocaproyl (MC) group. First reference patent claim 5 further limits the ADC of claim 4 wherein Z comprises a valine-citrulline (vc) group. First reference patent claims 7-9 further limit the ADC of claim 1 wherein, respectively: (i) the Ab is trastuzumab; (ii) p is 1, 2, 3, or 4; (iii) the ADC comprises a mixture of the antibody-drug conjugate compounds, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 2 to about 5. First reference patent claim 10 further limits claim 9 wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 3 to about 4. First reference patent claims 11-12 are drawn to a pharmaceutical composition comprising the ADC of claim 1 and a pharmaceutically acceptable diluent, carrier, or excipient, wherein the pharmaceutical composition may further comprise a therapeutically effective amount of a chemotherapeutic agent. First reference patent claim 15 further limits the ADC of claim 1, wherein the antibody binds to HER2. First reference patent claim 18 further limits the ADC of claim 1 wherein the ADC has the following structure: PNG media_image18.png 460 620 media_image18.png Greyscale However, it is noted that the first reference patent does not specifically claim anthracycline reagents, ADCs, and/or anthracycline derivatives thereof corresponding to PNU-159682 (i.e., anthracycline-based compounds wherein anthracycline is of instant formula (II)). These deficiencies are remedied by the teachings of Beria, as provided in the 103 section above. It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to substitute the anthracycline of the first reference patent with PNU-159682, taught by Beria, wherein such a substitution would yield the below listed structures: PNG media_image15.png 836 780 media_image15.png Greyscale One would have been motivated to make such a substitution to arrive at the above-listed structures because Beria teaches that PNU-159682 has been shown to be remarkably more cytotoxic than nemorubicin and doxorubicin in vitro, and was effective in vivo tumor models; thus one of ordinary skill in the art would have been motivated to substitute the anthracycline compound used by the first reference patent with PNU-159682 taught by Beria (i.e., substitute one anthracycline for another) because such a substitution would have reasonably been expected to yield compounds useful in making ADCs wherein said compounds and ADCs thereof would reasonably be expected to be useful in the treatment of, for example, cancer wherein the efficacy of anthracyclines, including those with structures of the first reference patent and PNU-159682, are established as well as their use in ADCs and synthetic approaches associated therewith. Claims 1-11, 17-18, and 51-24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 7-9, and 13 of U.S. Patent No. 8,389,697 (herein after referred to as “second reference patent”) in view of each of: US 8,900,589; US 8,389,697; and US 9,695,240. It is specifically noted that US 8,389,697 and US 9,695,240 are a continuation and a divisional, respectively, of US 8,900,589. As such, all three of the above-listed patents have the same disclosure. The teachings of the disclosure of US 8,900,589 (herein after referred to as “Beria”) are provided in the 103 section above. PNG media_image19.png 863 376 media_image19.png Greyscale Second reference patent claim 1 is drawn to an anthracycline derivative of formula (IIc), corresponding to Ant-L-(Z)m-X: PNG media_image20.png 724 390 media_image20.png Greyscale PNG media_image21.png 306 378 media_image21.png Greyscale Second reference patent claim 7 further limits the anthracycline derivate of claim 1 wherein the anthracycline derivate has the structure below: PNG media_image22.png 278 374 media_image22.png Greyscale Second reference patent claim 8 further limits the anthracycline derivate of claim 7 wherein the anthracycline derivate has the structure below: PNG media_image23.png 434 728 media_image23.png Greyscale Second reference patent claim 9 further limits the anthracycline derivative of claim 7 wherein the anthracycline derivative has the structure below: Second reference patent claim 13 further limits the anthracycline derivative of claim 1 wherein R1 and R2 are independently selected from a list of structures, wherein it is noted that said list of structures includes isopropyl (side chain of amino acid valine) and -(CH2)3NHCONH2 (side chain of amino acid citrulline). However, it is noted that the second reference patent does not specifically claim anthracycline reagents, ADCs, and/or anthracycline derivatives thereof corresponding to PNU-159682 (i.e., anthracycline-based compounds wherein anthracycline is of instant formula (II)), pharmaceutical compositions, or methods of treating cancer thereof. These deficiencies are remedied by the teachings of Beria, as provided in the 103 section above. It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to substitute the anthracycline of the second reference patent with PNU-159682, taught by Beria, wherein such a substitution would yield the below listed structures: PNG media_image15.png 836 780 media_image15.png Greyscale One would have been motivated to make such a substitution to arrive at the above-listed structures because Beria teaches that PNU-159682 has been shown to be remarkably more cytotoxic than nemorubicin and doxorubicin in vitro, and was effective in vivo tumor models; thus one of ordinary skill in the art would have been motivated to substitute the anthracycline compound used by the second reference patent with PNU-159682 taught by Beria (i.e., substitute one anthracycline for another) because such a substitution would have reasonably been expected to yield compounds useful in making ADCs wherein said compounds and ADCs thereof would reasonably be expected to be useful in the treatment of, for example, cancer wherein the efficacy of anthracyclines, including those with structures of the first reference patent and PNU-159682, are established as well as their use in ADCs and synthetic approaches associated therewith. Claims 1-11, 17-18, and 51-24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 3-5 of U.S. Patent No. 9,695,240 (herein after referred to as “third reference patent”) in view of each of: US 8,900,589; US 8,389,697; and US 9,695,240. It is specifically noted that US 8,389,697 and US 9,695,240 are a continuation and a divisional, respectively, of US 8,900,589. As such, all three of the above-listed patents have the same disclosure. The teachings of the disclosure of US 8,900,589 (herein after referred to as “Beria”) are provided in the 103 section above. Third reference patent claim 1 is drawn to a method of making an antibody-drug conjugate (ADC) compound comprising reacting an anthracycline derivative and an antibody (Ab) to form the ADC compound, wherein the anthracycline derivative is selected from a list of structures, wherein it is noted that said list of structures includes the structure reproduced below: PNG media_image24.png 378 521 media_image24.png Greyscale PNG media_image25.png 348 522 media_image25.png Greyscale wherein R is H, C1-C12 alkyl, or C6-C20 aryl; R1 and R2 are independently selected from an amino acid side chain; the antibody (Ab) is an antibody which binds to one or more tumor-associated antigens or cell surface receptors selected from (1)-(36) wherein it is noted that (17) is HER2 (ErbB2); and wherein the ADC compound is selected from a list of structures, wherein it is noted that said list of structures includes the structure reproduced below: Third reference patent claims 3-4 further limit the method of claim 1 wherein, respectively: (i) Ab is trastuzumab; and (ii) the ADC compound comprises a mixture of the ADC compounds, wherein the average drug loading per antibody in the mixture of ADC compounds is about 2 to about 5. Third reference patent claim 5 further limits claim 4 wherein the average drug loading per antibody in the mixture of ADC compounds is about 3 to about 4. However, it is noted that the third reference patent does not specifically claim anthracycline reagents, ADCs, and/or anthracycline derivatives thereof corresponding to PNU-159682 (i.e., anthracycline-based compounds wherein anthracycline is of instant formula (II)), pharmaceutical compositions thereof, nor methods of treating cancer. These deficiencies are remedied by the teachings of Beria, as provided in the 103 section above. It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to substitute the anthracycline of the third reference patent with PNU-159682, taught by Beria, wherein such a substitution would yield the below listed structures: PNG media_image15.png 836 780 media_image15.png Greyscale One would have been motivated to make such a substitution to arrive at the above-listed structures because Beria teaches that PNU-159682 has been shown to be remarkably more cytotoxic than nemorubicin and doxorubicin in vitro, and was effective in vivo tumor models; thus one of ordinary skill in the art would have been motivated to substitute the anthracycline compound used by the third reference patent with PNU-159682 taught by Beria (i.e., substitute one anthracycline for another) because such a substitution would have reasonably been expected to yield compounds useful in making ADCs wherein said compounds and ADCs thereof would reasonably be expected to be useful in the treatment of, for example, cancer wherein the efficacy of anthracyclines, including those with structures of the first reference patent and PNU-159682, are established as well as their use in ADCs and synthetic approaches associated therewith. Conclusion Claims 1-11, 17-18, and 21-24 are pending. Claims 1-11, 17-18, and 21-24 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALYSSA RAE STONEBRAKER whose telephone number is (571)270-0863. The examiner can normally be reached Monday-Thursday 7:00 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571)270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALYSSA RAE STONEBRAKER/Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

May 09, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780923
B7H3-TARGETING PROTEINS AND METHODS OF USE THEREOF
3y 11m to grant Granted Nov 03, 2026
Patent 12780937
ANTI-TROP-2 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF OR MUTANT THEREOF, AND MEDICAL USE THEREOF
3y 7m to grant Granted Nov 03, 2026
Patent 12780935
TREATMENT OF COMPLEMENT MEDIATED DISEASES AND DISORDERS WITH C3B ANTIBODIES
3y 1m to grant Granted Nov 03, 2026
Patent 12767729
ANTIBODIES AGAINST KLK5
4y 2m to grant Granted Oct 20, 2026
Patent 12760100
METHODS AND COMPOSITIONS TO IMPROVE THE SAFETY AND EFFICACY OF CELLULAR THERAPIES
5y 2m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+49.6%)
3y 5m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 116 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month